FindTrial
Sign In

STUDY OF THE EFFICACY OF KATUKADYA GHAN VATI IN MANAGEMENT OF HYPERTENSION.

STANDARD CONTROLLED RANDOMIZED CLINICAL STUDY OF THE EFFICACY OF KATUKADYA GHAN VATI IN MANAGEMENT OF UCHCHA-RAKTADAAB with special reference to ESSENTIAL HYPERTENSION.â??

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/11/016247
Enrollment
60
Registered
2018-11-01
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: Katukadya ghan vati: Katukadya ghan vati 500mg will be prepared in pharmacy & Standardization Will be done from recognized institute.Katukdya Ghan Vati 500mg 2BD for 30 days Control Int

Sponsors

carc college
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients having primary hypertension recently diagnosed. 2) Age : 30 to 70 years. 3) Gender : Irrespective of gender. 4) Stage 1 hypertension i. e. Systolic blood pressure is upto 160 mm of Hg &/or diastolic blood pressure upto100 mm of Hg.

Exclusion criteria

Exclusion criteria: 1) Hypertension Secondary to Any major Systemic illness. 2) Patient with known case of acute coronary syndrome, cardiomyopathies, Myocardial infarction, stroke. 3) Pregnant, lactating women & women on oestrogen replacement therapy. 4) Alcohol & drug abusers 5) Accelerated & malignant hypertension 6) Complicated multiple organ failure conditions. 7) Encephalopathy 8) Mentally ill patients

Design outcomes

Primary

MeasureTime frame
To assess the efficacy of the Katukadya Ghan Vati in uchcha raktdaab i.e. essential hypertension.Timepoint: To assess the efficacy of the Katukadya Ghan Vati in uchcha raktdaab i.e. essential hypertension in 30days—

Secondary

MeasureTime frame
1)To assess the efficacy of Atenolol in uchcha raktdaab i.e. essential hypertension. 2) To assess the adverse eventsTimepoint: For one month—

Countries

India

Contacts

Public ContactDrPranav Puranik

CARC college Nigadi,Pune

medhamaheshjoshi@gmail.com9881465798

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026